Long-term effects of intravenous pamidronate in fibrous dysplasia of bone
- 1 April 1994
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 343 (8903), 953-954
- https://doi.org/10.1016/s0140-6736(94)90069-8
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Mineralisation defects with pamidronate therapy for Paget's diseaseThe Lancet, 1993
- Bisphosphonates: A New Class of Drugs in Diseases of Bone and Calcium MetabolismPublished by Springer Science and Business Media LLC ,1989
- Polyostotic fibrous dysplasia with contrasting responses to calcitonin and mithramycin: Aetiological and therapeutic implicationsIrish Journal of Medical Science, 1988
- Panostotic fibrous dysplasia: A congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia, and hypophosphatemiaAmerican Journal of Medical Genetics, 1983
- Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome).Endocrinologia Japonica, 1983
- A Case of Albright's Syndrome Treated with CalcitoninActa Orthopaedica, 1979
- Effects of Calcitonin in Metastatic Bone Carcinoma, Osteoporosis, Polyostotic Fibrous Dysplasia and HypercalcemiaEndocrinologia Japonica, 1971
- Effects of Calcitonin in Paget's Disease and Polyostotic Fibrous DysplasiaJournal of Clinical Endocrinology & Metabolism, 1970